Figure S6 from Targeting AKT with Oridonin Inhibits Growth of Esophageal Squamous Cell Carcinoma <i>in Vitro</i> and Patient-Derived Xenografts <i>in Vivo</i>
Maoyong Song,Xuejiao Liu,Kangdong Liu,Ran Zhao,Hai Huang,Yuanyuan Shi,Man Zhang,Silei Zhou,Haiyang Xie,Hanyong Chen,Yin Li,Yufeng Zheng,Qiong Wu,Fangfang Liu,En‐Min Li,Ann M. Bode,Zigang Dong,Mee-Hyun Lee
DOI: https://doi.org/10.1158/1535-7163.22506771.v1
2023-01-01
Abstract:Oridonin attenuates the growth of PDX tumors in mice. (A) The effect of oridonin on the volume of PDX tumors (EG9) was plotted over 40 days. Vehicle or oridonin (40 or 160 mg/kg) was administered by gavage. Tumor volume was measured twice a week. The asterisk (* p < 0.05) indicates a significant decrease in volume of tumors from oridonin-treated mice compared to vehicle-treated mice. Data are shown as mean values {plus minus} S.E. (B) Body weight of mice (EG9) was plotted over 40 days. (C) The photographs show tumors from PDX mice treated with vehicle or oridonin (40 mg/kg or 160 mg/kg). (D) The expression of Ki-67, pAKT, pGSK-3β or p-mTOR was examined by IHC analysis (100X magnification; upper panel). The expression of Ki-67, pAKT, pGSK-3β or p-mTOR was quantified from 4 separate areas on each slide and an average of 5 (vehicle) or 6 (oridonin-treated) samples per group (lower panel). Data are expressed as IOD values {plus minus} S.D. The asterisks (* p < 0.05, ** p < 0.01) indicate a significant decrease in Ki-67, pAKT (Ser473), pGSK-3β (Ser9) or p-mTOR (Ser2448) in treated tissues compared to untreated controls. (E) Characteristic information of patients (EG9 and HEG18) whose tumors were used in the PDX mouse model. (F) H&E staining (left panel) and weights of spleen and liver (right panel) in EG9 and HEG18 tissues.